WO2006116541A3 - Tat-002 and methods of assessing and treating cancer - Google Patents
Tat-002 and methods of assessing and treating cancer Download PDFInfo
- Publication number
- WO2006116541A3 WO2006116541A3 PCT/US2006/015904 US2006015904W WO2006116541A3 WO 2006116541 A3 WO2006116541 A3 WO 2006116541A3 US 2006015904 W US2006015904 W US 2006015904W WO 2006116541 A3 WO2006116541 A3 WO 2006116541A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tat
- expression
- methods
- identification
- activity
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Surprisingly, the present inventors have discovered that expression of TAT-002 protein in human patients is associated with cancer, and that the over-expressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-002 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-002 expression or activity, comprising: contacting a candidate compound with a TAT-002 and detecting the presence or absence of binding between said compound and said TAT-002, or detecting a change in TAT-002 expression or activity. Methods are also included for the identification of compounds that modulate TAT-002 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-002 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67519105P | 2005-04-27 | 2005-04-27 | |
US60/675,191 | 2005-04-27 | ||
US67675205P | 2005-04-29 | 2005-04-29 | |
US60/676,752 | 2005-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006116541A2 WO2006116541A2 (en) | 2006-11-02 |
WO2006116541A3 true WO2006116541A3 (en) | 2007-04-19 |
Family
ID=37215470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/015904 WO2006116541A2 (en) | 2005-04-27 | 2006-04-27 | Tat-002 and methods of assessing and treating cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006116541A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110946114A (en) * | 2019-12-06 | 2020-04-03 | 福建正大食品有限公司 | Camellia chicken feeding method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087831A2 (en) * | 2002-04-11 | 2003-10-23 | Oxford Glycosciences (Uk) Ltd | Proteins involved in breast cancer |
US20030220240A1 (en) * | 2000-12-21 | 2003-11-27 | Tang Y. Tom | Vesicle trafficking proteins |
-
2006
- 2006-04-27 WO PCT/US2006/015904 patent/WO2006116541A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220240A1 (en) * | 2000-12-21 | 2003-11-27 | Tang Y. Tom | Vesicle trafficking proteins |
WO2003087831A2 (en) * | 2002-04-11 | 2003-10-23 | Oxford Glycosciences (Uk) Ltd | Proteins involved in breast cancer |
Non-Patent Citations (1)
Title |
---|
AGRAWAL N. ET AL.: "RNA Interference: Biology, Mechanism, and Application", MICRO MOL. BIOL. REV., vol. 67, 2003, pages 657 - 685, XP009030438 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006116541A2 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gomes et al. | Chaperone-mediated autophagy prevents cellular transformation by regulating MYC proteasomal degradation | |
Hadzic et al. | The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion | |
WO2009005809A3 (en) | Compositions and methods for treating and diagnosing cancer | |
NO20074389L (en) | Determination of responders to chemotherapy | |
CL2007003649A1 (en) | An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70. | |
NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
WO2011119934A3 (en) | Methods and materials for detecting colorectal neoplasm | |
MX349513B (en) | Material and methods for treating or preventing her-3 associated diseases. | |
UA105760C2 (en) | Bst2 antibody | |
WO2008103849A3 (en) | Methods and compounds for lymphoma cell detection and isolation | |
WO2005094348A3 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
WO2020107002A3 (en) | Methods for expansion of natural killer (nk) cell subset and related compositions and methods | |
MX2013011431A (en) | Methods for predicting and improving the survival of gastric cancer patients. | |
WO2009073575A3 (en) | Methods for treating induced cellular proliferative disorders | |
WO2007055966A3 (en) | Therapies for cancer using rlip76 | |
MX2009001070A (en) | Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma. | |
WO2006083957A3 (en) | Tat-001 and methods of assessing and treating cancer | |
NO20091662L (en) | Novel antigens and antibodies associated with pancreatic, ductal adenocarcinoma | |
WO2006133145A3 (en) | Tat-007 and methods of assessing and treating cancer | |
WO2006116681A3 (en) | Tat-003 and methods of assessing and treating cancer | |
WO2006116541A3 (en) | Tat-002 and methods of assessing and treating cancer | |
WO2007005559A3 (en) | Tat-005 and methods of assessing and treating cancer | |
WO2009019366A3 (en) | Aminoacylase 1 assay method for the in vitro diagnosis of colorectal cancer | |
WO2007089793A3 (en) | Tat-041 and methods of assessing and treating cancer | |
WO2007089690A3 (en) | Tat-042 and methods of assessing and treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06758642 Country of ref document: EP Kind code of ref document: A2 |